Kazunori Hirokawa Executive Vice President and CFO PLAY LIST from the beginning Top Management Presentation Financial Results of FY2017 Q3 (April 1 - December 31, 2017) Forward-Looking Statements Agenda FY2017 Q3 Financial Results Overview of FY2017 Q3 Results Revenue Operating Profit Profit Attributable to Owners of the Company Revenue: Major Business Units (incl. Forex Impact) Revenue: Major Products in Japan FY2017 Revised Consolidated Forecast FY2017 Revised Consolidated Forecast Edoxaban (Lixiana) Lixiana : For Maximization of Product Value R&D Update DS-8201: Broad and Bold Program DS-8201: P1 Study Design DS-8201: Patient Background DS-8201: P1 Study Part 1+2b Efficacy(1) DS-8201: P1 Study Part 1+2b Efficacy(2) DS-8201: P1 Study Part 1+2b Efficacy(3) DS-8201: CT Imaging of PR DS-8201: Adverse Events >20% (N=45) DS-8201: Conclusions at ASCO GI DS-8201: Rationale of Neratinib Combo Appendix R&D Milestone Events Major R&D Pipeline Out-licensing Projects Lixiana: Growth in Japan(1) Lixiana: Growth in Japan(2) Lixiana: Growth in Germany and South Korea Growth of Injectafer Abbreviations @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Back Next